April 22, 2018
April 22, 2018 – Charlottesville, Virginia – Kevin Eisenfrats, Co-Founder and CEO of Contraline, Inc., will be sharing the history, current-state-of-the-art, and innovation in vas-occlusive medical devices in a featured talk at the American Society of Andrology 43rd Annual Conference in Portland, Oregon. His talk, titled “The Past, Present, and Future of Vas-Occlusive Medical Devices,” will be part of the symposium on male contraception on April 24th.
The commercialization potential of methods to occlude the vas deferens have promise to be the first long-lasting, non-hormonal, and reversible male contraceptive approach. “With about half of all pregnancies unplanned, and the burden of birth control mostly shouldered by women, there is a huge need for effective male contraception,” said Kevin Eisenfrats. “Contraline is dedicated to developing a long-acting, reversible contraceptive (LARC) for men and we are honored to be included among other leading researchers pursuing male contraceptive approaches.”
Other speakers in the symposium include Dr. Daniel Johnston, Chief of the NIH Contraception Research Branch; Dr. Stephanie Page from the University of Washington; and Dr. Michael O’Rand from the University of North Carolina. The symposium will highlight funding available for male contraceptive research, as well as provide updates on various hormonal and non-hormonal male contraceptive drugs in development.
Contraline is a medical device company developing novel hydrogels for reproductive and contraceptive applications. The Company is focused on providing couples with new options for male contraception with a long-acting, non-hormonal, and reversible device. Contraline’s first product in development is Adam, which applies cutting-edge hydrogel technology to physically block sperm within the male reproductive tract.